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I N V I T E D  E D I T O R I A L
Editorial: intended victim or innocent bystander? The liver in 
COVID-19
Two recent, single-centre retrospective studies from China and 
Italy assessed the relationships between liver enzyme abnor-
malities and mortality in COVID-19 patients.1,2 Although the 
authors used identical thresholds to define liver enzyme abnor-
malities and liver injury, they arrived at slightly different conclu-
sions. Huang et al reported that liver injury (>3× ULN for ALT) 
was associated with significantly increased adjusted hazards of 
mechanical ventilation and death.1 They opined that this may 
reflect a SARS-CoV-2 viral hepatitis. Ponziani et al also showed 
that admission liver enzymes abnormalities were associated with 
significantly increased odds of ICU admission, but did not repli-
cate the findings that peak or baseline transaminases were sig-
nificantly associated with mortality.2 They observed that enzyme 
derangements were mild, transient and temporally associated 
with IL-6 levels, potentially suggesting an inflammatory mecha-
nism. Why were the findings so different?
Although there were key differences between the studies (see 
Table 1), there was also convergence. 95 ± 3% of patients in both se-
ries did not experience liver injury. Both observed that enzyme levels 
(particularly ALT) increased with disease severity, whether assessed 
by ICU admission or severity grading. Enzyme levels in both hospital-
ised cohorts tended to increase over the first 2-3 weeks of admission 
before slowly normalising. Both studies reconfirmed that COVID-19 
is more likely to be severe and fatal in older and male patients and 
showed associations between white cell abnormalities (relative lymph-
openia and relative neutrophilia) and adverse outcomes. This leaves 
the divergence in findings regarding the relation between (peak) liver 
enzyme levels and mortality. However, the Italian study did find that 
baseline liver enzyme derangement was significantly associated with 
ICU admission, which itself was significantly associated with mortality. 
The results of these studies are, therefore, broadly in agreement—in 
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Huang et al1 Ponziani et al2 P valuea 
Setting Wuhan, China Rome, Italy n/a
Number hospitalised: n 675 448 n/a
Age of all hospitalised: 
(Median (IQR))
Not expressed, but ~10 years less 
than in (2) at each quartile
68 (55-78) n/a
Males: n (%) 313 (46%) 286 (64%) <0.0001
Known CLDx 27 (4%) 6 (1.3%) 0.0106




with no admission 
liver abnormalities: 
n (%)
422 (63%) 294 (66%) ns
Number hospitalised 
with admission liver 
injury: n (%)
25 (3.7%) 10 (2.2%) ns
Severe status or ICU 
admission: n (%)
53 (8%) 77 (17%) <0.0001
30-d mortality, 
estimated from article 
figures (%)
~15% Unknown but 
>15%
n/a
aBetween study comparisons were made with Fisher's exact test, using Graph Pad Prism v 8.4.2. 
TA B L E  1   Comparison of Huang et al's1 
and Ponzani et al's2 studies published in 
this edition of the journal. Key differences 
in determinants of immune function and 
poor COVID-19 outcome such as age 
and gender are notable which in addition 
to other unmeasured factors may have 
contributed to some differences in results 
between the studies
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COVID-19, liver derangements are common, usually mild, are associ-
ated with severity, and gradually resolve in survivors.
What do these results mean for understanding COVID-19-related 
enzyme abnormalities? Acute liver failure has not been appreciably 
reported in COVID-19 despite ~12 000 000 known global cases in 
6 months (expected to equate to ~1.2 000 000 cases SARS-CoV-2 as-
sociated liver enzyme abnormalities on the basis of Ponziani's non-hos-
pitalised patients).3 Post-mortem studies remain equivocal,4 and 
suspicions of SARS-CoV-2 hepatitis are unlikely to abate.5 However, 
potentially contributory aetiologies for COVID-19-related enzyme 
abnormalities abound, particularly in severe SARS-CoV-2-related ill-
ness. These include systemic inflammatory response with risk of he-
patic ischaemia and hypoxia, widespread microthrombi formation and 
drug-induced liver injury.6 Liver enzyme abnormalities are commonly 
associated with adverse outcomes in non-viral systemic diseases,7 and 
COVID-19 prediction tools incorporate bilirubin rather than transami-
nases.8 It is perhaps possible that the predominant aetiology may vary 
over disease course, with an early viral and later more inflammatory 
phase of SARS-Cov-2 illness6. Notably the most efficacious treatment 
demonstrated for COVID-19 is an immunosuppressant rather than an 
anti-viral, the effect size of which is greatest in patients where liver dys-
function is most common.9,10 Regardless of one's views regarding the 
existence of SARS-CoV-2 viral hepatitis, clinical evidence still suggests 
that abnormal liver enzymes in acute COVID-19 remain a sideshow.
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